Influence of CYP2D6 polymorphisms on symptomatology and side-effects of patients with schizophrenia in Malaysia

Malaysian Journal of Medical Sciences

Volumn 16, Issue 3, 2009, Pages 13-21

  Zahari, Zalina ^a,b   Salleh, Mohd Razali ^c   Teh, Lay Kek ^d   Ismail, Rusli ^a  

^a INSTITUTE FOR RESEARCH IN MOLECULAR MEDICINE INFORMM   (Malaysia)

^b HOSPITAL UNIVERSITI SAINS MALAYSIA   (Malaysia)

^c SCHOOL OF MEDICAL SCIENCES   (Malaysia)

^d UNIVERSITI TEKNOLOGI MARA   (Malaysia)

Author keywords

Cytochrome P450 CYP2D6; Neurosciences; Schizophrenia; Treatment outcomes

Indexed keywords

CHLORPROMAZINE; CLOZAPINE; CYTOCHROME P450 2D6; FLUPENTIXOL; FLUPHENAZINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; SULPIRIDE; TRIFLUOPERAZINE; TRIHEXYPHENIDYL; ZUCLOPENTHIXOL;

ADULT; AKATHISIA; ARTICLE; BARNES AKATHISIA RATING SCALE; CONTROLLED STUDY; DNA EXTRACTION; DRUG RESPONSE; EXTRAPYRAMIDAL SYMPTOM; FEMALE; GENE DUPLICATION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALAYSIA; MALE; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; POSITIVE AND NEGATIVE SYNDROME SCALE; PROGNOSIS; RATING SCALE; SCHIZOPHRENIA; SIMPSON ANGUS SCALE;

EID: 73449115327     PISSN: 1394195X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. McDonald C, Murphy KC. The new genetics of schizophrenia. Psychiatr Clin North Am 2003;26:41-63.
2. Kirov G, O'Donovan MC, Owen MJ. Finding schizophrenia genes. J Clin Invest. 2005; 115:1440-1448.
3. Kane JM. Pharmacologic treatment of schizophrenia. Biol Psychiatry 1999; 46:1396-1408.
4. Hariri AR, Lewis DA. Genetics and the future of clinical psychiatry. Am J Psychiatry. 2006;163:1676-1678.
5. Krebs M, Leopold K, Hinzpeter A, Schaefer M. Current schizophrenia drugs: efficacy and side effects. Expert Opin Pharmacother. 2006;7:1005-1016.
6. Malhotra AK, Murphy GM Jr, Kennedy JL. Pharmacogenetics of psychotropic drug response. Am J Psychiatry. 2004;161:780-796.
7. Siegle I, Fritz P, Eckhardt K, Zanger UM, Eichelbaum M. Cellular localization and regional distribution of CYP2D6 mRNA and protein expression in human brain. Pharmacogenetics. 2001; 11: 237-245.
8. Cai WM, Nikoloff DM, Pan RM, de Leon J, Fanti P, Fairchild M et al. CYP2D6 genetic variation in healthy adults and psychiatric African-American subjects: implications for clinical practice and genetic testing. Pharmacogenomics J. 2006; 6: 343-350.
9. Ingelman-Sundberg M, Oscarson M, McLellan RA. Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment. Trends Pharmacol Sci. 1999;20:342-349.
10. Miksys SL, Cheung C, Gonzalez FJ, Tyndale RF. Human CYP2D6 and mouse CYP2Ds: organ distribution in a humanized mouse model. Drug Metab Dispos 2005; 33: 1495-1502.
11. Sistonen J, Sajantila A, Lao O, Corander J, Barbujani G, Fuselli S. CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure. Pharmacogenet Genomics. 2007;17:93-101.
12. Linder MW, Prough RA, Valdes R Jr. Pharmacogenetics: a laboratory tool for optimizing therapeutic efficiency. Clin Chem 1997;43:254-266.
13. Sachse C, Brockmoller J, Bauer S, Roots I. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet. 1997; 60:284-295.
14. Zanger UM, Raimundo S, Eichelbaum M. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol. 2004;369:23-37.
15. Gardiner SJ, Begg EJ. Pharmacogenetics, drugmetabolizing enzymes, and clinical practice. Pharmacol Rev. 2006;58:521-590.
16. Zanger UM, Fischer J, Raimundo S, Stüven T, Evert BO, Schwab M et al. Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6. Pharmacogenetics 2001; 11:573-585.
17. Johansson I, Lundqvist E, Bertilsson L, Dahl ML, Sjoqvist F, Ingelman-Sundberg M. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci USA. 1993;90:11825-11829.
18. Bertilsson L, Dahl ML, Dalen P, Al-Shurbaji A. Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. Br J Clin Pharmacol 2002;53:111-122.
19. Jaanson P, Marandi T, Kiivet RA, Vasar V, Vään S, Svensson JO et al. Maintenance therapy with zuclopenthixol decanoate: associations between plasma concentrations, neurological side effects and CYP2D6 genotype. Psychopharmacology (Berl). 2002;162:67-73.
20. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988; 16: 1215.
21. Teh LK, Ismail R, Yusoff R, Hussein A, Isa MN, Rahman AR. Heterogeneity of the CYP2D6 gene among Malays in Malaysia. J Clin Pharm Ther. 2001;26:205-211.
22. Hamelin BA, Dorson PG, Pabis D, Still D, Bouchard RH, Pourcher E et al. CYP2D6 mutations and therapeutic outcome in schizophrenic patients. Pharmacotherapy. 1999;19:1057-1063.
23. Panagiotidis G, Arthur HW, Lindh JD, Dahl ML, Sjöqvist F. Depot haloperidol treatment in outpatients with schizophrenia on monotherapy: impact of CYP2D6 polymorphism on pharmacokinetics and treatment outcome. Ther Drug Monit. 2007;29:417-422.
24. Plesničar BK, Zalar B, Breskvar K, Dolžan V. The influence of the CYP2D6 polymorphism on psychopathological and extrapyramidal symptoms in the patients on long-term antipsychotic treatment. J Psychopharmacol. 2006;20:829-833.
25. Ohmori O, Kojima H, Shinkai T, Terao T, Suzuki T, Abe K. Genetic association analysis between CYP2D6*2 allele and tardive dyskinesia in schizophrenic patients. Psychiatry Res. 1999; 87:239-244.
26. Tiwari AK, Deshpande SN, Rao AR, Bhatia T, Lerer B, Nimgaonkar VL et al. Genetic susceptibility to tardive dyskinesia in chronic schizophrenia subjects: III. Lack of association of CYP3A4 and CYP2D6 gene polymorphisms. Schizophr Res. 2005;75:21-26.
27. Arthur H, Dahl ML, Siwers B, Sjoqvist F. Polymorphic drug metabolism in schizophrenic patients with tardive dyskinesia. J Clin Psychopharmacol. 1995;15:211-216.
28. Scordo MG, Spina E, Romeo P, Dahl ML, Bertilsson L, Johansson I et al. CYP2D6 genotype and antipsychotic-induced extrapyramidal side effects in schizophrenic patients. Eur J Clin Pharmacol. 2000;56: 679-683.
29. Brockmöller J, Kirchheiner J, Schmider J, Walter S, Sachse C, Müller-Oerlinghausen B et al. The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment. Clin Pharmacol Ther. 2002;72:438-452.